Comparative interactions of organic Ca++ channel antagonists with myocardial Ca++ and K+ channels

Insights

Three calcium channel blockers, D-600, nisoldipine, and diltiazem, inhibit calcium and potassium currents in frog heart cells. Selectivity for calcium channels varies among these drugs.

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology

Background:

  • Calcium channel antagonists are crucial in treating cardiovascular diseases.
  • Understanding their effects on different ion channels is vital for drug development.

Purpose of the Study:

  • To investigate the dose-dependent effects of D-600, nisoldipine, and diltiazem on calcium (iCa) and potassium (iK) currents in single frog atrial cells.
  • To determine the selectivity of these antagonists for cardiac calcium versus potassium channels.

Main Methods:

  • Utilized the voltage clamp technique on isolated frog atrial cells.
  • Administered varying concentrations of D-600, nisoldipine, and diltiazem.
  • Measured inward calcium current (iCa) and delayed, outward potassium current (iK).

Main Results:

  • Low concentrations selectively inhibited iCa, suggesting iK is not primarily calcium-activated.
  • Higher concentrations inhibited both iCa and iK.
  • D-600 and nisoldipine showed greater selectivity for Ca++ channels than diltiazem.
  • Potassium current inhibition was voltage-dependent, contrasting with calcium current inhibition.

Conclusions:

  • D-600 and nisoldipine are more selective calcium channel blockers than diltiazem in frog atrial cells.
  • The study provides insights into the differential effects and voltage-dependent mechanisms of these calcium channel antagonists on cardiac ion currents.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...